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Patients with ‘high cholesterol’ are a com-
mon occurrence in general practice.They
often present with a high cholesterol level
determined at a pharmacy, at work or for
insurance purposes. Irrespective of where
and how the test was done, the GP is usu-
ally left with the responsibility of inter-
preting the result and deciding on further
management. Getting the initial assess-
ment and management right can pro-
foundly influence the patient’s future
health, both physically and financially!
Depending on the clinical context, a lipid
value that may be of little concern in one
patient will clearly indicate therapy with
lipid-lowering drugs in another patient.
Getting it wrong means that some
patients are denied access to therapy that
may significantly reduce mortality, while
others take expensive and unnecessary
therapy for many years. Failure to recog-
nise the genetic nature of a dyslipidaemia
results in a missed opportunity for family
screening and prevention of premature
ischaemic heart disase (IHD) in 
individuals at very high risk.
Cardiovascular disease remains the lead-
ing cause of mortality. Given the long-
term implications of any decision regard-
ing risk management, it is worthwhile
investing time in a thorough consultation
and discussion with the patient. A clear
understanding of the disease and the ben-
efits of long-term therapy will often result




Dyslipidaemia is associated with two
major complications. Atherosclerosis is
most commonly associated with dyslipi-
daemia, but pancreatitis secondary to
severe hypertriglyceridaemia is the most
dangerous in the short term.A hyper-
triglyceridaemia of more than 10 - 15
mmol/l (or patients with lipaemic (white)
serum) is a medical emergency. Such
hypertriglyceridaemic patients must be
evaluated immediately and should urgent-
ly be referred to a centre with lipid exper-
tise. Delaying management or choosing
the incorrect drug could result in pancre-
atitis and even death.
As atherosclerosis is the commonest com-
plication of dyslipidaemia, this article will
focus mainly on the evaluation of patients
with pure hypercholesterolaemia or mixed
hyperlipidaemias that are not associated
with pancreatitis.
History
It is useful to define the purpose of a con-
sultation. Does the patient want advice for
an incidentally discovered hyperlipidaemia
or was the dyslipidaemia found after an
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Clinical approach to 
dyslipidaemia
High cholesterol is a common general practice
problem. This article guides the GP on its 
m a n a g e m e n t .
Failure to realise the
genetic nature of a dys -
lipidaemia results in a




(IHD) in individuals at
very high risk.
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ischaemic event?  Does the patient
have other cardiovascular risk fa c-
t o rs or a fa m i l y history of prema-
ture heart disease?  Were lipids
specifically screened? Did the
patient present with pancreatitis or
one of the physical signs of lipid
disorders?
Taking a history proceeds along
standard lines, but particular atten-
tion should be paid to the follow-
ing points.
The dyslipidaemia
When was the dyslipidaemia first
discovered and what was the range
of lipid tests? If the patient is on
lipid-lowering drugs, can a baseline
untreated lipid profile be traced?
Was the sample taken in the fasting
state (important for triglyceride
values, which fluctuate much more
than cholesterol values)? Was the
sample taken during an acute-
phase response (> 24 h after a
myocardial infarction (MI) or any
severe stressor (e.g. surgery, severe
influenza)) when cholesterol values
will be falsely low? Are there other
diseases or drugs that could be
causing the hyperlipidaemia? (See
article on secondary dyslipidaemia
on p. 365 of this issue of CME.)
Complications of the 
dyslipidaemia
Is there a history of IHD, cere-
brovascular disease, peripheral vas-
cular disease or aortic aneurysm?
Has the patient had pancreatitis or
severe unexplained abdominal
pain?
Additional risk factors for 
atherosclerosis
Is the patient diabetic or hyperten-
sive? Specifically ask about smok-
ing, both current and previous. Try
to estimate the number of pack
ye a rs ((cigarettes per day/20 × ye a rs ) )
smoked and ask whether the
patient has considered or previous-
ly tried quitting. How did the
patient try to quit and what was
the reason for failure?
Family histor y
Taking a good family history is
particularly important in dyslipi-
daemic patients, especially in
South Africa where there is a par-
ticularly high prevalence of severe
monogenic disorders of lipid
metabolism.The family history is
best taken while sketching a family
tree, to which as much information
as possible is added.Ask about
lipid values in family members or
whether anybody is taking medica-
tion for ‘cholesterol problems’. In
South Africa founder effects are
seen for familial hypercholesterol-
aemia (FH).This means that in
some population groups the preva-
lence of FH is extremely high, up
to 1:70 compared with the average
of 1:500 worldwide. In South
Africa Afrikaners, Lithuanian Jews,
Indians and Christian Lebanese
are at particular risk of FH, so ask-
ing about the ancestry of your
patient is important. As cardiovas-
cular disease is so common it is
important to ascertain whether it
has occurred prematurely in the
family. Generally an MI in men
younger than 50 years or women
under 55 years is considered to be
premature cardiovascular disease.
A family history of premature IHD
may indicate a genetic disorder
with greatly increased risk, while
late-onset cardiovascular disease in
family members does not have the
same implication.The metabolic
syndrome (and ultimately type II
diabetes in some patients) also has
a heritable component, and a fami-
ly history of diabetes means a high-
er risk of diabetes for the patient,
especially if he or she is overweight
or has a sedentary lifestyle.
Box 1, together with Fig. 1, are
examples of a family tree indicating
autosomal-dominant inheritance
and premature IHD in a family
with familial hypercholesterol-
aemia.The family tree also illus-
trates the inheritance of the prob-
lem to the patients and helps to
decide which relatives are at risk
and should be screened.
Box 1. Family tree illustrating
the inheritance of familial
hypercholesterolaemia
The family tree (Fig. 1) was
drawn from information provided
by the patient (arrow) at his first
visit. Squares represent males
and circles represent females. A
line through the symbol indicates
that the person is deceased. Half-
shading of symbols indicates that
the individual has presumed FH
(based on lipid values or prema-
ture heart disease). In this family
the patient inherited FH from his
father who had a fatal myocardial
infarction (MI) at 45 years of
age. His father’s sister also died
of a premature MI.The mutated
gene can be traced back even fur-
ther to his paternal grandmother,
as she also had premature IHD.
The grandmother was of
Afrikaner origin. Although one of
the patient’s maternal uncles also
died of an MI, his death was not
premature.The patient did not
know the lipid values of his two
living older brothers and
although they are well, they may
still have inherited FH.The
patient and his siblings have a
total of 19 children. Two of these
children have FH based on their
lipid values, while FH has been
excluded in 5 children by lipid
testing. Each of the 5 children of
the oldest brother has a 50%
chance of being affected and
needs to be screened.The 3 chil-
dren of the youngest brother are
unlikely to be affected, as their
father’s cholesterol level is not
raised.The risk for the remaining
4 children cannot be quantified
and their father should be
screened initially.
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Dietary history
The patients’ diet can rapidly be
assessed by simply asking them to
describe what they eat on a typical
day and how their food is pre-
pared. Try to assess how much f at
is being consumed overall and
what the spread is between saturat-
ed, monounsaturated and polyun-
saturated fat. Cholesterol intake is
determined by the amount and
type of animal products consumed.
All muscle tissue (meat) contains
about 75 mg cholesterol per 100 g.
Egg yolks contain about 250 mg
cholesterol and organ meat is high-
er in cholesterol.A brief dietary
history is worth while even if the
patient will be seeing a dietitian, as
one can quickly judge whether a
patient claiming to be on a ‘low-
cholesterol diet’ has really changed
the diet adequately. Knowing how
‘bad’ the diet was previously gives
one a feel for the expected
improvement in the lipid profile
with dietary modification.
Exercise
Patients should be asked specifical-
ly about their exercise habits and
level of physical activity. This is
usually a good opportunity to
explain the benefits of regular exer-
cise on cardiovascular health.
Examination
Special attention needs to be given
to the following points when examin-
ing the dyslipidaemic patient.
Clinical evidence of vascular
disease
All peripheral pulses should be pal-
pated and major vessels auscultat-
ed. Measure the blood pressure
and examine the heart and fundi.
Patients with clinically manifest
vascular disease have a very high
risk of further complications and
most will require lipid-lowering
therapy as part of secondary pre-
vention.
Evidence for secondary dyslipi-
daemia
Look for evidence of liver, renal or
thyroid disease.Abdominal obesity,
acanthosis nigricans and excessive
skin tags may be a marker of
insulin resistance and the metabol-
ic syndrome.
Physical signs of dyslipidaemia
The physical signs of dyslipidaemia
are easily found if looked for. As a
general rule cholesterol deposits in
tendons (thickening, irregularity,
xanthomata), while hypertriglyceri-
daemia causes skin infiltration
(eruptive or tubo-eruptive xan-
thomata, palmar crease infiltra-
tion). In extreme hypercholesterol-
aemia (usually in patients with
homozygous familial hypercholes-
terolaemia) both skin and tendon
infiltration may be found. Severe
genetic mixed hyperlipidaemias,
such as dysbetalipoproteinaemia,
may also affect both skin and ten-
dons.
Finding the signs of 
hyperlipidaemia
Look for the following:
• Xanthelasma are not specific
for any lipid disorder and many
patients with xanthelasma will
not be dyslipidaemic. However,
they should be screened for dys-
lipidaemia if this has not already
been done.
• The prevalence of arcus
cornealis increases with age and
is therefore of most diagnostic
value if found in patients under
the age of 40 years. Arcus
cornealis in young patients gen-




eyelid may often hide a superior
arcus. Lift the eyelid and ask the
patient to look down.
• Eruptive xanthomata (Fig. 2)
are associated with severe hyper-
triglyceridaemia and urgent mea-
sures are required as the risk of
pancreatitis is very high.
• Palmar crease xanthomata —
yellow infiltrations of the palmar
crease — are rare.They are diag-
nostic of dysbetalipopro-
teinaemia.
• Tuberous xanthomata are gen-
erally found in severe hypercho-
lesterolaemia, while tuboeruptive
xanthomata are associated with
Fig. 1. Family tree illustrating the inheritance of familial hypercholesterolaemia.
COAD = chronic destructive airways disease.
Fig. 2. Eruptive xanthomata. The
patient initially presented to a derma-
tologist with a rash. He had newly
diagnosed diabetes and his triglyc-
eride level was 85 mmol/l. There is
probably some (minor) genetic predis-
position aggravated by the diabetes.
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mixed hyperlipidaemia. Fig. 3
shows a tuberous xanthoma at
the ankle. Tuberous xanthomata
are most commonly found at the
elbows.
• Tendon xanthomata can be
seen or felt as nodules that move
with the tendon.They are firm
and non-compressible, which
helps to distinguish them from
ganglia.The best places to look
are the extensor tendons of the
hands and the Achilles tendons.
In Fig. 3 the nodule in the
Achilles tendon is a xanthoma.
The Achilles tendons are palpat-
ed to assess their dimensions
(one’s own tendons can be used
for comparison if no genetic
hyperlipidaemia is present) and
to feel for any irregularities,
roughness or lumps.
• In patients with severe hyper-
triglyceridaemia there may be
two additional clues to the prob-
lem. Lipaemic (white) serum
can be observed if the blood is
left undisturbed for a while after
venesection, but lipaemia may be
observed directly on fundoscopy
(lipaemia retinalis ). Fig. 4
shows lipaemic serum after the
blood has been centrifuged.
Laboratory tests
Initial screening for dyslipidaemia
is often done with a random cho-
lesterol measurement. If the cho-
lesterol is elevated (> 5 mmol/l) it
should be followed up by a fasting
lipid profile. In the lipid profile
total cholesterol, triglyceride and
HDL cholesterol levels are mea-
sured, while the low-density
lipoprotein (LDL) cholesterol level
is usually calculated from the
above values. Remember that if
triglyceride levels are elevated the
cholesterol level will also be high,
because the lipoproteins carrying
triglycerides also contain choles-
terol.The commonest problem in
patients with extreme hypercholes-
terolaemia (> 15 mmol/l) is severe
hy p e rt ri g l y c e ri d a e m i a . Lipoprotein (a)
measurement adds extra cost, and
is most useful in patients with bor-
derline indications for lipid-lower-
ing drugs. A high Lp (a) would
influence one to treat a patient
with borderline risk. As lipoprotein
(a) is not much influenced by
lipid-lowering therapy (except
niacin) it should not be measured
repeatedly on follow-up.
Further useful laboratory investiga-
tions at the initial consultation
include:
• Urine dipstick to screen for
renal disease.
• Renal function tests .
Abnormalities alert to renal dis-
ease as a cause of secondary dys-
lipidaemia, and with significant
renal impairment dosages of
lipid-modifying drugs, especially
fibrates, may require adjustment.
• Thyroid-stimulating hormone
(TSH) . Hypothyroidism is a
common cause of secondary dys-
lipidaemia and is often clinically
occult.
• Fasting glucose. The metabolic
syndrome is a common cause of
secondary dyslipidaemia and is
characterised by insulin resis-
tance, which may result in
impaired glucose tolerance or
even frank diabetes. Diabetes is
associated with markedly
increased cardiovascular risk.
• Baseline liver function tests.
These tests screen for underlying
hepatic disease, such as cholesta-
sis, which may result in sec-
ondary dyslipidaemia. Liver
function may also be a pointer to
alcohol abuse or non-alcoholic
steatohepatitis (NASH).
Transaminase levels may increase
on statin therapy, and it is impor-
tant to have baseline values.
• Creatinine kinase (CK).
Measuring CK at baseline pro-
vides a useful reference point if
patients should develop muscle
problems when using statins. If
the CK level is raised at baseline
the patient should be evaluated




Deciding on the diagnosis
It is worthwhile to try making a
more precise diagnosis than simply
saying ‘high cholesterol or high
triglycerides’. If a specific diagnosis
is made, deciding on therapy is
easier and the risk for other family
members can be better quantified.
Initially consider the lipid pheno-
type. Is there predominant hyper-
cholesterolaemia, hypertriglyceri-
daemia or is a mixed hyperlipi-
daemia present? 
Fig. 4. Lipaemic serum is associated
with severe hypertriglyceridaemia and
carries a high risk of pancreatitis.
Fig. 3. Achilles xanthomata. This
patient has the unusual combination
of a tuberous xanthoma at the ankle
and a xanthoma in the Achilles ten-
don.
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In patients with predominant
hypercholesterolaemia consider the
following categories:
• Most patients will have poly -
genic hypercholesterolaemia .
Their total cholesterol is usually
between 5 and 7.5 mmol/l and
they do not have tendon xan-
thomata or a family history of
severe hyperlipidaemia or prema-
ture heart disease.
• Patients with monogenic disor -
der s of lipid metabolism (FH,
familial binding defective
apoB100 (FBD) and familial
combined hyperlipidaemia
(FCH)) usually have a total cho-
lesterol level of more than 7.5
mmol/l.There is often a family
history of hyperlipidaemia or
premature heart disease. Patients
with FH or FBD may have ten-




• Primary hypertriglycer i-
daemia. This occurs in patients
with genetic defects of lipopro-
tein metabolism. Primary hyper-
triglyceridaemia may be reces-
sively inherited (the parents have
normal lipid values).The risk is
increased in consanguinous mar-
riages and each child of the cou-
ple has a 25% chance of being
affected. Hypertriglyceridaemia
is present from birth and pancre-
atitis may occur in infancy. Other
primary hypertriglyceridaemias
may present in adulthood.
• Secondary hypertriglycer i-
daemia. This is much more
common than primary hyper-
triglyceridaemia. Patients with
secondary hypertriglyceridaemia
have a limited capacity to
metabolise triglyceride-rich
lipoproteins, but can maintain
normal lipid values in the
absence of additional ‘stresses’
on the system. If triglyceride pro-
duction is increased or metabo-
lism further impaired, severe
hypertriglyceridaemia results.
Examples of such ‘second hits’
are obesity, diabetes, alcohol
abuse or drug therapy.
In patients with mixed hyperlipi-
daemia consider the following cate-
gories:
• Genetic causes . These include
FCH and dysbetalipopro-
teinaemia.The inheritance of
FCH is autosomal dominant and
can cause varied lipoprotein phe-
notypes in affected family mem-
bers. Dysbetalipoproteinaemia
causes a severe mixed hyperlipi-
daemia and in most cases the
inheritance is recessive.
• Polygenic mixed hyperlipi-
daemia.This results from the
interaction of multiple ill-defined
genetic and environmental fac-
tors such as diet and exercise.
Deciding on management
With all the necessary information
at hand, deciding on future man-
agement is often not difficult. All
patients should be counselled to
stop smoking, exercise regularly
and follow a diet low in saturated
fat and cholesterol, emphasising
unsaturated and omega-3 polyun-
saturated fat. Medical conditions
affecting cardiovascular risk, such
as diabetes or hypertension, should
be optimally managed. Secondary
dyslipidaemia should be excluded
and causative factors reversed (if
possible) before considering lipid-
lowering drugs.
Severe hypertriglyceridaemia 
(>10 mmol/l) requires urgent
attention. Patients should be
referred to or discussed with staff
Some common cholesterol myths busted
• ‘I can’t have a cholesterol problem because I am not fat.’
Adipose tissue contains triglyceride. Although obesity is associated with
an increased prevalence of dyslipidaemia it certainly is not a prerequisite!
Patients with monogenic lipid disorders may be extremely thin and fit and
still have markedly raised lipid levels.
• ‘I feel well,therefore my cholesterol must be normal.’
Hypercholesterolaemia is a “silent killer’.There are generally no symp-
toms until vascular complications set in.
• ‘Diet does not work and it is easier to take pills.’
The lipid profile after dietary changes improves variably, depending on
the previous diet and the individual’s metabolic set-up. Even if the lipid
levels do not decrease dramatically, changing the nature of fatty acids con-
sumed has a beneficial effect on, for instance, platelet adhesiveness and
cardiac arrhythmogenicity. Diet and lifestyle changes have proven effects
on mortality and morbidity (with many dietary studies reporting better
reductions in mortality than statin studies) and medication alone is there-
fore not ‘the full deal’. Having an inherited hyperlipidaemia is also no rea-
son to disregard the diet!
• ‘All hypercholesterolaemia is genetic and therefore fate.’
Only a small minority of hypercholesterolaemic patients have an identifi-
able genetic disorder.The majority are hypercholesterlaemic because they
have a susceptible genetic background and are exposed to negative envi-
ronmental influences. If the environment is corrected fate can be reversed!
• ‘Avocados contain cholesterol.’
For practical purposes no plant contains any cholesterol at all. Plants do
contain sterol molecules, but these are different from cholesterol and not
absorbed by humans. Advertising plant products (e.g. cooking oil) as cho-
lesterol-free is therefore correct, but another product on the shelf will be
just as cholesterol-free if it is of pure plant origin.
at a lipid clinic, or referred to a
specialist with experience in dyslip-
idaemia. Patients with hypercholes-
terolaemia or mixed hyperlipi-
daemia (without severe hyper-
triglyceridaemia) are not at imme-
diate risk and can be managed
stepwise with initial lifestyle modi-
fication, followed by titration of
lipid-lowering medication if indi-
cated.
Patients with clinically overt vascu-
lar disease are at very high risk of
further events and require ‘sec-
ondary prevention’. If they do not
achieve their LDL cholesterol tar-
get of less than 3 mmol/l on
lifestyle modification alone, drug
therapy is necessary. Following the
results of the recent Heart
Protection Study many would
argue that in the setting of sec-
ondary prevention statins should
be used even in patients who do
not have elevated lipid values by
conventional definition.
When assessing patients without
clinically overt atherosclerosis it is
important to distinguish between
patients with monogenic lipid dis-
orders and those with polygenic/
moderate hyperlipidaemia.
Monogenic lipid disorders increase
cardiovascular risk dramatically
and almost all patients will need
therapy with lipid-lowering drugs.
Patients with FH should have their
partner’s cholesterol checked
before starting a family and be
counselled about the risk of having
a child with homozygous FH.
Once a patient has been diagnosed
with a monogenic lipid disorder
attempts should be made to screen
other potentially affected family
members. During family screening
children with hyperlipidaemia are
often identified.The decision at
which age to start lipid-lowering
therapy is often difficult and a con-
sultation at a lipid clinic can be
very helpful.
The majority of patients seen in a
general practice will have polygenic
hypercholesterolaemia.The indica-
tion for lipid-lowering therapy in
these patients is based on their
absolute risk of an MI during the
next 10 years. For young patients
the risk can be projected to 60
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Section A: Men
Age (yrs) 30 - 34 35 - 39 40 - 44 45 - 49 50 - 54 55 - 59 60 - 64 65 - 69 70 - 74
Points -1 0 1 2 3 4 5 6 7
TC (mmol/l) < 4.1 4.2 - 5.2 5.3 - 6.2 6.3 - 7.2 >7.2
Points -3 0 1 2 3
HDLC (mmol/l) < 0.91 0.91 - 1.16 1.17 - 1.55 > 1.55
Points 2 1 0 -2
BP (mmHg) < 130/< 85 130 - 139/85 - 89 140 - 159/90 - 99 ≥ 160/≥ 100
Points 0 1 2 3
Other Non-smoker Smoker Not diabetic Diabetic
Points 0 2 0 2
Section B: Women
Age (yrs) 30 - 34 35 - 39 40 - 44 45 - 49 50 - 54 55 - 59 60 - 74
Points -9 -4 0 3 6 7 8
TC (mmol/l) < 4.1 4.2 - 5.2 5.3 - 7.2 >7.2
Points -2 0 1 3
HDLC (mmol/l) < 0.91 0.91 - 1.16 1.17 - 1.29 1.3 - 1.55 > 1.55
Points 5 2 1 0 -3
BP (mmHg) < 120/< 80 120 - 139/80 - 89 140 -159/90 - 99 ≥ 160/≥ 100
Points -3 0 2 3
Other Non-smoker Smoker Not diabetic Diabetic
Points 0 2 0 4
Section C: Risk (% of cohort who will have MI in next 10 years)
Points -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Men 2 3 3 4 5 7 8 10 13 16 20 25 31 37 45 >53
Women 1 2 2 2 3 3 4 4 5 6 7 8 10 11 13 15 18 20 24 > 27
Section D: Risk for population (% who will have MI in 10 years)
Age (yrs) 30 - 34 35 - 39 40 - 44 45 - 49 50 - 54 55 - 59 60 - 64 65 - 69 70 - 74
Men 3 5 7 11 14 16 21 25 30
Women < 1 < 1 2 5 8 12 12 13 14
TC = total cholesterol; H DLC = high-density lipoprotein cholesterol; BP = blood pressure; MI = myocardial infarction. 
Table I. 
years of age. Absolute risk is calcu-
lated using risk calculation tables
derived from data gathered during
the Framingham study. Table I
illustrates the currently recom-
mended risk calculation in South
Africa.This calculation can be
done in less than a minute.The
calculation incorporates age and
sex as non-modifiable variables.
The clinical variables are blood
pressure, smoking status and dia-
betes. The laboratory variables are
total cholesterol (used as a surro-
gate for LDL-cholesterol) and
HDL-cholesterol levels. Lipid-low-
ering therapy is recommended if
the absolute risk for MI is more
than 20%, despite lifestyle modifi-
cation.
With regard to Table I, to derive
the absolute risk as a percentage of
subjects who will develop MI over
10 years, add the points for each
risk category. For men consult
section A and for women, section
B. For the BP score, use the high-
est score of either diastolic or sys-
tolic pressure. The risk associated
with the total points is derived
from section C for men and
women. The average population
risk from which the data were
derived is given in section D over
various age intervals. The follow-
ing risk factors are not included:
obesity, family history, definite
diagnosis of monogenic lipid disor-
der (to be considered in cases
where cholesterol concentration is
> 7.5 mmol/l) and sedentary
lifestyle.These factors should be
borne in mind when assessing
global risk. Note that the score is
gender dependent: men with 9 risk
points have the same 20% risk as
women with 15 risk points. To
extrapolate the risk to age 60 years,
add the difference between the age
points for age 60 - 64 years and
those for the current age to the
total score.
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IN A NUTSHELL
Dyslipidaemia is common in general
practice and a major risk factor for
atherosclerosis.
Severe hypertriglyceridaemia 
( > 10 mmol/l) can cause pancreatitis
and may be associated with eruptive
xanthomata and lipaemic serum.
The assessment of dyslipidaemic
patients should focus on the exclu-
sion of secondary disorders, global
evaluation of cardiovascular risk,
lifestyle evaluation and identification
of monogenic lipid disorders.
Tendon xanthomata are always patho-
logical and are diagnostic of a mono-
genic lipid disorder.
Taking a family history is very impor-
tant to identify monogenic disorders.
Screening the family of patients with
monogenic lipid disorders will reduce
the incidence of premature IHD by
identifying for treatment those who
are at high risk.
Patients with monogenic lipid disor-
ders are at a very high risk for devel-
oping cardiovascular disease and
almost all require lipid-lowering drugs.
Patients with clinically evident vascu-
lar disease have an LDL-cholesterol
target of ≤ 3 mmol/l.
Patients with polygenic dyslipidaemia
and no vascular disease should be
given lipid-lowering drugs if their cal-
culated risk of MI is more than 20%
during the next 10 years after lifestyle
modification.
Lifestyle interventions are very effec-
tive and cheap and should be applied
to all patients.
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SINGLE SUTURE
Fasting reduces cholesterol 
During the month of Ramadan, observant Muslims typically change their eating habits from three meals a
day to two. A small study compared 28 men with high lipid concentrations who ‘fasted’ during Ramadan and
10 men with normal lipid concentrations who did not fast, and found that a low-fat, low-calorie diet made
no difference to the non-fasters. It produced a significant reduction in cholesterol concentrations and energy
intake, however, for those who fasted.
(Saudi Medical Journal 2003; 24: 184-188.) 
